Ipsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment for Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen announced that its New Drug Application (NDA) for palovarotene, an oral, investigational, selective RARγ agonist ...
Read more